Cosmos Health Inc. (NasdaqCM:COSM) has entered into a purchase agreement to acquire Cloudscreen on October 11, 2023. The planned acquisition of Cloudscreen® encompasses the software, its registered trademark, and associated know-how. The founders of Cloudscreen® and its senior scientific team would continue to lead and manage the research, initiation, and execution of new drug repurposing projects.

As a starting point, Cloudscreen's team is anticipated to undertake five repurposing projects, with the potential for each project to lead to patent filing upon successful completion of the in vitro validation phase. Cloudscreen's founders and its senior scientific team will continue to lead the research and execution of new drug repurposing projects